Artículos seleccionados

El experto opina

Artículos seleccionados

Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)

Annemans L, Aymé S, Le Cam Y, Facey K, Gunther P, Nicod E, et al. Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL). Orphanet J Rare Dis. 2017; 12: 50

Comentado por:

Jaime Espín
Profesor de la Escuela Andaluza de Salud Pública

Sustainable public health systems for rare diseases

Ferrelli RM, Egle Gentile A, De Santis M, Taruscio D. Sustainable public health systems for rare diseases. Ann Ist Super Sanita. 2017; 53(2): 170-175.

Comentado por:

Marta Trapero-Bertran
Profesora titular e investigadora de la Universitat Internacional de Catalunya (UIC)

Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen

Giannuzzi V, Conte R, Landi A, Ottomano SA, Bonifazi D, Baiardi P, et al. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen. Orphanet J Rare Dis. 2017; 12: 64

Comentado por:

Jaime Espín
Profesor de la Escuela Andaluza de Salud Pública

Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research

Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. © World Health Organization 2015. Regional Office for Europe

Comentado por:

Albert Figueras
Profesor del Departamento de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona

Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries

Gammie T, Lu CY, Babar ZU-D. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. PLoS ONE. 2015; 10(10): e0140002.

Comentado por:

Jorge Mestre-Ferrandiz
Director de Consultoría. Office of Health Economics. Londres.

Página 2 de 3